Furumachi Kazuhiro, Kagatsume Tatsuki, Higuchi Akari, Kozaru Mariko, Kumagai Etsuko, Hosohata Keiko
Department of Nephrology, Kenwakai Hospital, Nagano, Japan.
Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Infect Drug Resist. 2024 Aug 29;17:3759-3767. doi: 10.2147/IDR.S475917. eCollection 2024.
The aim of the study was to determine the association between coronavirus disease 2019 (COVID-19) infection and diabetes management indices in patients with type 2 diabetes mellitus.
A single-center, retrospective, observational study of patients with type 2 diabetes mellitus at Kenwakai Hospital (Nagano, Japan) was conducted. Data of 95 patients (mean age, 72 ± 12 years; men, 67.4%) who visited between March 1, 2019 and February 28, 2022 were obtained from the hospital's electronic information system. COVID-19 was diagnosed by a chemiluminescent enzyme immunoassay (CLEIA).
There was no association between COVID-19 infection and age, sex, hemodialysis treatment status, or the Charlson Comorbidity Index. After adjustment for possible confounding factors, the incidence of COVID-19 infection was significantly correlated with HbA1c ≥7.0% (odds ratio [OR], 5.51; 95% confidence interval [CI], 1.30-23.26).
The results suggest an association between high HbA1c levels and COVID-19 infection in patients with type 2 diabetes mellitus. Appropriate management of diabetes mellitus, focusing on HbA1c levels, may help prevent COVID-19 infection and severe disease after infection.
本研究旨在确定2型糖尿病患者中2019冠状病毒病(COVID-19)感染与糖尿病管理指标之间的关联。
对日本长野县Kenwakai医院的2型糖尿病患者进行了一项单中心、回顾性观察研究。从医院电子信息系统获取了2019年3月1日至2022年2月28日期间就诊的95例患者的数据(平均年龄72±12岁;男性占67.4%)。COVID-19通过化学发光酶免疫分析(CLEIA)诊断。
COVID-19感染与年龄、性别、血液透析治疗状态或查尔森合并症指数之间无关联。在对可能的混杂因素进行调整后,COVID-19感染的发生率与糖化血红蛋白(HbA1c)≥7.0%显著相关(优势比[OR]为5.51;95%置信区间[CI]为1.30 - 23.26)。
结果表明2型糖尿病患者中高HbA1c水平与COVID-19感染之间存在关联。以HbA1c水平为重点的糖尿病适当管理可能有助于预防COVID-19感染以及感染后的重症疾病。